• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regulatory/Compliance

Sanofi’s Suliqua combination therapy approved in European Union

January 18, 2017 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) said today that the European Commission granted marketing authorization in Europe for its Suliqua combination product for adults with type II diabetes. The therapy is a fixed-ratio combination of basal insulin glargine and lixisenatide, intended to be used with metformin to improve patients’ glycemic control. Suliqua will be available in 2 pre-filled SoloSTAR pens at […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Sanofi-Aventis

Pulmatrix shares soar after winning FDA designation

January 17, 2017 By Sarah Faulkner

Pulmatrix

Pulmatrix (NSDQ:PULM) shares were up 159% to $1.79 apiece in mid-afternoon trading today after the company announced that its drug candidate for treating fungal infections in the lungs of cystic fibrosis patients was designated as a ‘qualified infectious disease product’ by the FDA. With the designation, the Lexington, Mass.-based company will receive 5 years of […]

Filed Under: Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

South Korean medical device regulatory changes updates

January 17, 2017 By Danielle Kirsh

By Stewart Eisenhart, Emergo Group Enforcement dates for various new and updated medical device regulations in South Korea have now gone into effect, according to Emergo consultants in Seoul. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not necessarily reflect those […]

Filed Under: Regulatory/Compliance Tagged With: Emergo Group

Dexcom surges on Medicare nod for continuous glucose monitors

January 13, 2017 By Sarah Faulkner

Dexcom

DexCom (NSDQ:DXCM) said yesterday that the Centers for Medicare & Medicaid classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company’s Dexcom G5 Mobile is the only CGM system that falls under this classification, according to San Diego, Calif.-based DexCom, since patients can make treatment decisions using the device. DXCM […]

Filed Under: Diabetes, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Abbott Laboratories, Centers for Medicare and Medicaid Services (CMS), DexCom Inc., Senseonics, Tandem Diabetes Care

Keystone Nano wins FDA nod for nanoliposome cancer treatment

January 5, 2017 By Sarah Faulkner

Keystone Nano launches clinical trial for NanoLiposome cancer therapy

Keystone Nano said today that the FDA approved its investigational new drug application for the ceramide nanoliposome as a treatment for solid tumors. The company will launch a phase I trial at 3 sites to evaluate safe dosing levels and the product’s efficacy as a cancer therapy. Ceramide is a lipid that has demonstrated efficacy in […]

Filed Under: Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Regulatory/Compliance Tagged With: Keystone Nano

Neurelis wins fast track designation from FDA for intranasal diazepam spray

January 4, 2017 By Sarah Faulkner

Neurelis closes Series B for intranasal diazepam spray

Neurelis, Inc. said today that it won fast track designation from the FDA for its intranasal diazepam spray. The  nasal formulation of diazepam, which is being developed for pediatric and adult epilepsy patients who experience repititive or cluster seizures, is in the final stage of clinical development, according to Neurelis. The company expects to submit […]

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Neurelis Inc.

Ocular Therapeutix touts data from phase III trial of Dextenza

January 4, 2017 By Sarah Faulkner

Ocular Therapeutix

Ocular Therapeutix (NSDQ:OCUL) touted interim data today from its phase III trial of Dextenza for the treatment of post-surgical ocular inflammation and pain. The bioresorbable intracanalicular hydrogel plug is designed to release drugs at the ocular surface for up to 30 days. The company announced last month that Dextenza met the trial’s 2 primary efficacy endpoints: […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Hydrogels, Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Ocular Therapeutix

FDA accepts Allergan’s new drug application for Liletta contraception device

January 4, 2017 By Sarah Faulkner

Allergan

Allergan (NYSE:AGN) and the global nonprofit women’s health company Medicines360 said today that the FDA accepted its supplemental New Drug Application for the Liletta contraception device. The companies are asking the federal watchdog to extend the system’s duration of use from 3 years to 4 years. Liletta is a levonorgestrel-releasing intrauterine system that is placed […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Women's Health Tagged With: Allergan, Medicines360

Biogen, Ionis win FDA approval for first spinal muscular atrophy drug

December 28, 2016 By Sarah Faulkner

Biogen

Biogen (NSDQ:BIIB) said last week that it won FDA approval for its spinal muscular atrophy treatment, Spinraza. The drug is the 1st treatment approved in the U.S. for spinal muscular atrophy, a progressive and often fatal genetic disease that causes muscle weakness in infants and toddlers. The FDA previously granted Biogen’s application fast track designation […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Biogen Idec, Ionis Pharmaceuticals

Another warning for CareFusion’s Alaris drug pump

December 22, 2016 By Sarah Faulkner

CareFusion logo

The U.K.’s Medicines & Healthcare Products Regulatory Agency issued a warning today for Carefusion‘s Alaris syringe drug pumps. The UK watchdog said that Alaris pumps with broken springs in the plunger assembly could accidentally release a single dose of medication if the pump also uses non-recommended syringes. “This problem comes about through a combination of using […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: CareFusion

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 100
  • Page 101
  • Page 102
  • Page 103
  • Page 104
  • Interim pages omitted …
  • Page 106
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS